Document is current
Any future updates will be listed below
-
Authors
Novis, Elan
Tan, Joyce
Vignati, Danielle
Wong, Terence
Rawson, Robert V.
Stretch, Jonathan R.
Lo, Serigne N.
Pennington, Thomas E.
Ch’ng, Sydney
Shannon, Kerwin F.
Spillane, Andrew J.
Nieweg, Omgo E.
Thompson, John F.
Rtshiladze, Michael
Scolyer, Richard A.
Saw, Robyn P. M.
-
Funding
Funding for this research was provided by:
University of Sydney
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 22 March 2025
First Online: 28 April 2025
Disclosure
: Robyn P.M. Saw has received honoraria for Advisory Board participation from MSD and Clinical Laboratories Pty Ltd. Richard A. Scolyer has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, Amgen Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. Robert V. Rawson has received honoraria from MSD for educational presentations and advisory board participation. Sydney Ch’ng has received fees for professional services from SkylineDx and MSD. Elan Novis, Joyce Tan, Danielle Vignati, Terence Wong, Jonathan Stretch, Serigne N. Lo, Thomas E. Pennington, Kerwin F. Shannon, Andrew J. Spillane, Omgo E. Nieweg, John F. Thompson, and Michael Rtshiladze have no conflicts of interest to declare that may be relevant to the contents of this study.
